ClinicalTrials.gov record
Completed Phase 1 Interventional Results available

A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

ClinicalTrials.gov ID: NCT02564198

Public ClinicalTrials.gov record NCT02564198. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 3:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors

Study identification

NCT ID
NCT02564198
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
29 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Months to 21 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 10, 2015
Primary completion
Jul 15, 2019
Completion
Jul 15, 2019
Last update posted
Aug 16, 2021

2015 – 2019

United States locations

U.S. sites
21
U.S. states
18
U.S. cities
21
Facility City State ZIP Site status
Childrens Hospital of Alabama Birmingham Alabama 35233
Children's Oncology Group Monrovia California 91016
Childrens Hospital of Orange County Orange California 92868
University of California, San Francisco San Francisco California 94158
Children's National Medical Center Washington D.C. District of Columbia 20010-2970
Children's Healthcare of Atlanta at Scottish Rite Atlanta Georgia 30322
Ann & Robert H Lurie Children's Hospital of Chicago Chicago Illinois 60611
Riley Hospital for Children Indianapolis Indiana 46202
Mark O Harfield-Warren Grant Magnuson Clinical Center Bethesda Maryland 20892
University of Michigan Health Systems Ann Arbor Michigan 48109
University of Minnesota Hospital Minneapolis Minnesota 55455
Washington University Medical School St Louis Missouri 63110
Columbia University Medical Center New York New York 10032
Children's Hospital Medical Center Cincinnati Ohio 45229-3039
Oregon Health and Science University Portland Oregon 97239
Children's Hospital of Philadelphia Philadelphia Pennsylvania 19104
Childrens Hospital of Pittsburgh Pittsburgh Pennsylvania 15224
St Jude Childrens Research Hospital Memphis Tennessee 38105
Texas Childrens Hospital Houston Texas 77030
Seattle Children's Hospital Research Foundation Seattle Washington 98105
Medical College of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02564198, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 16, 2021 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02564198 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →